EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The combined effect of metformin and mirabegron on diet‐induced obesity

Xin-Yuan Zhao, Ying Liu, Xuan Zhang, Ben-Chi Zhao, George Burley, Zhi-Can Yang, Yi Luo, An-Qi Li, Ruo-Xin Zhang, Zhi-Ying Liu, Yan-Chuan Shi, Qiao-Ping Wang iD

MedComm · 2023-04 · 4 (2)

DOI: 10.1002/mco2.207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 14.02.2023. Verfasst von Xin-Yuan Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Metabolism and Aging School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-sen University Sun Yat-sen University Shen…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐obesity medications act by suppressing energy intake (EI), promoting energy expenditure (EE), or both. Metformin (Met) and mirabegron (Mir) cause weight loss by targeting EI and EE, respectively. However, anti‐obesity effects during concurrent use of both have yet to be explored. In this study, we investigated the anti‐obesity effects, metabolic benefits, and underlying mechanisms of Met/Mir combination therapy in two clinically relevant contexts: the prevention model and the treatment model. In the prevention model, Met/Mir caused further 12% and 14% reductions in body weight (BW) gain induced by a high‐fat diet compared to Met or Mir alone, respectively. In the treatment model, Met/Mir additively promoted 17% BW loss in diet‐induced obese mice, which was 13% and 6% greater than Met and Mir alone, respectively. Additionally, Met/Mir improved glucose tolerance and insulin sensitivity. These benefits of Met/Mir were associated with increased EE, activated brown adipose tissue thermogenesis, and white adipose tissue browning. Significantly, Met/Mir did not cause cardiovascular dysfunction in either model. Together, the combination of Met and Mir could be a promising approach for the prevention and treatment of obesity by targeting both EI and EE simultaneously.

Schlagwörter

Stichwörter der Autor:innen

combination therapy for obesityenergy expenditurefood intakemetforminthermogenesisβ3‐adrenergic receptor agonist

Autor:innen und Institutionen

  • Laboratory of Metabolism and Aging School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat-sen University Sun Yat-sen University Shenzhen China.
  • Obesity and Metabolic Disease Research Group Diabetes and Metabolism Division Garvan Institute of Medical Research Sydney New South Wales Australia.
  • School of Clinical Medicine St Vincent's Clinical Campus Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia.

ORCID-Profile: Qiao-Ping Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, X. Y., Liu, Y., Zhang, X., Zhao, B. C., Burley, G., Yang, Z. C., Luo, Y., Li, A. Q., Zhang, R. X., Liu, Z. Y., Shi, Y. C., & Wang, Q. P. (2023). The combined effect of metformin and mirabegron on diet‐induced obesity. MedComm, 4(2). https://doi.org/10.1002/mco2.207

Vancouver

Zhao XY, Liu Y, Zhang X, Zhao BC, Burley G, Yang ZC, et al. The combined effect of metformin and mirabegron on diet‐induced obesity. MedComm. 2023;4(2). doi:10.1002/mco2.207

BibTeX
@article{Zhao2023,
  author = {Zhao, Xin-Yuan and Liu, Ying and Zhang, Xuan and Zhao, Ben-Chi and Burley, George and Yang, Zhi-Can and Luo, Yi and Li, An-Qi and Zhang, Ruo-Xin and Liu, Zhi-Ying and Shi, Yan-Chuan and Wang, Qiao-Ping},
  title = {The combined effect of metformin and mirabegron on diet‐induced obesity},
  journal = {MedComm},
  year = {2023},
  volume = {4},
  number = {2},
  doi = {10.1002/mco2.207}
}
Kostenlos starten →